Loutfi S Aboussouan

Dr. Loutfi S Aboussouan

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2005 in The Lancet
Verified
Journal Article
Closed access
JSJames K Stoller
James K Stoller
LALoutfi S Aboussouan
Loutfi S Aboussouan

1 February 2012 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
JSJames K. Stoller
James K. Stoller
LALoutfi S Aboussouan
Loutfi S Aboussouan
α1-Antitrypsin (AAT) deficiency is an underrecognized genetic condition that affects approximately 1 in 2,000 to 1 in 5,000 individuals and predisposes to liver disease and early-onset emphysema. AAT is mainly produced in the liver and functions to protect the lung against proteolytic damage (e.g., from neutrophil elastase). Among the approximately 120 variant alleles described to date, the Z allele is most commonly responsible for severe deficiency and disease. Z-type AAT molecules polymerize within the hepatocyte, precluding secretion into the blood and causing low serum AAT levels (∼ 3–7 μM with normal serum levels of 20–53 μM). A serum AAT level of 11 μM represents the protective threshold value below which the risk of emphysema is believed to increase. In addition to the usual treatments for emphysema, infusion of purified AAT from pooled human plasma—so-called “augmentation therapy”—represents a specific therapy for AAT deficiency and raises serum levels above the protective threshold. Although definitive evidence from randomized controlled trials of augmentation therapy is lacking and therapy is expensive, the available evidence suggests that this approach is safe and can slow the decline of lung function and emphysema progression. Promising novel therapies are under active investigation.

15 September 1997 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
LALoutfi S Aboussouan
Loutfi S Aboussouan
SKSaeed U. Khan
Saeed U. Khan
DMDavid P. Meeker
David P. Meeker
KSKay Stelmach
Kay Stelmach
HMHiroshi Mitsumoto
Hiroshi Mitsumoto
Noninvasive positive-pressure ventilation may benefit patients with amyotrophic lateral sclerosis and respiratory insufficiency. To determine 1) whether patients tolerant of noninvasive positive-pressure ventilation have better survival than intolerant patients and 2) whether bulbar symptoms account for intolerance of noninvasive positive-pressure ventilation. Observational cohort study. Tertiary care referral center. 39 patients with amyotrophic lateral sclerosis who were treated with noninvasive positive-pressure ventilation. Noninvasive positive-pressure ventilation was started for patients with new orthopnea, new hypercapnia, or both. Patients were divided into two groups: those tolerant of and those intolerant of noninvasive positive-pressure ventilation. The risk for death from onset of respiratory insufficiency was higher for intolerant patients than for tolerant patients (relative risk, 3.1 [95% CI, 1.8 to 9.6]). Moderate or severe bulbar symptoms were more prevalent among intolerant patients than among tolerant patients (67% compared with 33%; P = 0.04). Among patients with amyotrophic lateral sclerosis, those who are tolerant of noninvasive positive-pressure ventilation have better survival than do those who are intolerant. Bulbar symptoms partially account for intolerance of noninvasive positive-pressure ventilation.

1 May 2015 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
LALoutfi S Aboussouan
Loutfi S Aboussouan
Sleep-disordered breathing in neuromuscular diseases is due to an exaggerated reduction in lung volumes during supine sleep, a compromised physiologic adaptation to sleep, and specific features of the diseases that may promote upper airway collapse or heart failure. The normal decrease in the rib cage contribution to the tidal volume during phasic REM sleep becomes a critical vulnerability, resulting in saw-tooth oxygen desaturation possibly representing the earliest manifestation of respiratory muscle weakness. Hypoventilation can occur in REM sleep and progress into non-REM sleep, with continuous desaturation and hypercarbia. Specific characteristics of neuromuscular disorders, such as pharyngeal neuropathy or weakness, macroglossia, bulbar manifestations, or low lung volumes, predispose patients to the development of obstructive events. Central sleep-disordered breathing can occur with associated cardiomyopathy (e.g., dystrophies) or from instability in the control of breathing due to diaphragm weakness. Mitigating factors such as recruitment of accessory respiratory muscles, reduction in REM sleep, and loss of normal REM atonia in some individuals may partially protect against sleep-disordered breathing. Noninvasive ventilation, a standard-of-care management option for sleep-disordered breathing, can itself trigger specific sleep-disordered breathing events including air leaks, patient–ventilator asynchrony, central sleep apnea, and glottic closure. These events increase arousals, reduce adherence, and impair sleep architecture. Polysomnography plays an important role in addressing pitfalls in the diagnosis of sleep-disordered breathing in neuromuscular diseases, identifying sleep-disordered breathing triggered by noninvasive ventilation, and optimizing noninvasive ventilation settings.

1 October 2000 in SLEEP
Verified
Journal Article
Open access
PDF file
JRJames A. Rowley
James A. Rowley
LALoutfi S Aboussouan
Loutfi S Aboussouan
MBM. Safwan Badr
M. Safwan Badr
To prospectively study the utility of four clinical prediction models for either predicting the presence of obstructive sleep apnea (OSA, apnea-hypopnea index [AHI] ≥ 10/hour), or prioritizing patients for a split-night protocol (AHI ≥20/hour). All patients presenting for OSA evaluation completed a research questionnaire that included questions from previously developed clinical prediction models. The probability of sleep apnea for each patient for each model was calculated based upon the equation used in the model. Based upon two cutoffs of apnea-hypopnea index, 10 and 20, the sensitivity, specificity, and positive predictive value were calculated. For the cutoffs AHI ≥10 and ≥20, receiver operating characteristic curves were generated and the areas under the curves calculated. Comparisons of demographic information and symptom response were compared between patients with and without OSA, and men vs. women. Urban, accredited sleep disorders center. All patients referred for evaluation of OSA who underwent polysomnography. N/A 370 patients (191 men, 179 women) completed the study. 248 of the 370 (67%) patients had an AHI≥10; 180 of the 370 (49%) had an AHI≥20. For AHI ≥10, the sensitivities ranged from 76 to 96%, specificities from 13%–54%, positive predictive values from 69%–77% using the probability cutoff of the original investigators; the areas under the curve from 0.669 to 0.736. For AHI≥20, the areas under the ROC curves ranged from 0.700 to 0.757; using cutoffs to maximized specificity, the sensitivities ranged from 33%–39%, specificities from 87%–93%, and positive predictive values from 72%–85%. All the models performed better for men. The clinical prediction models tested are not be sufficiently accurate to discriminate between patients with or without OSA but could be useful in prioritizing patients for split-night polysomnography.

1 September 2009 in Chest
Verified
Journal Article
Closed access
RKRoop K Kaw
Roop K Kaw
Adrian V. HernandezAdrian V. Hernandez
Adrian V. Hernandez
EWEsteban Walker
Esteban Walker
LALoutfi S Aboussouan
Loutfi S Aboussouan
BMBabak Mokhlesi
Babak Mokhlesi